ShareValue scores for DVA: Valuation 81, Quality 74, Growth 44, Health 38.

DVA
NYSE

DaVita HealthCare Partners Inc

$194.82(+1.12%)

Updated

Loading chart...
Sentiment

Pulse

Rating

Moderate

Trap Risk

P/E to median

Not enough data
Valuation
81
Undervalued

vs US-listed mid-cap Healthcare stocks

Price vs Value
Quality
74
Strong
Business Strength
Growth
44
Moderate
Revenue & Earnings
Health
38
Stressed
Financial Stability
Price trend
46
Neutral
Separate from the four scores

Company Details

About

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.

Score Analysis

AI Investment Thesis

Data as of:Nov 6, 2026

By using ShareValue.ai you agree to our Terms and Privacy Policy. Educational platform, not investment advice.